Oramed Pharmaceuticals (ORMP) risk factors
Item 1A of every Oramed Pharmaceuticals Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2025 10-K risk factors41 risks6 new15 dropped9 reworded
Oramed faces significant risks from ongoing clinical trial uncertainties for its oral insulin capsule and heavy reliance on strategic investments like Alpha Tau and Scilex loans. The company also implemented a poison pill defense and maintains extensive operations and research activities in Israel.
Filed Mar 26, 2026 - FY2024 10-K risk factors50 risks
Oramed faces critical risks from the failed Phase 3 oral insulin trial and ongoing strategic transaction evaluations. Financial stability heavily depends on the Scilex note repayment and maintaining Nasdaq compliance. The company navigates joint ventures, vaccine development uncertainties, and potential equity dilution.
Filed Mar 27, 2025